Ligand Pharmaceuticals (LGND) announced the launch of Pelthos Therapeutics, a biopharmaceutical company. Pelthos is a wholly owned subsidiary of Ligand. Pelthos is committed to commercializing therapeutic products to help patients impacted by diseases with limited treatment options. The company's lead product is ZELSUVMI topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. ZELSUVMI is expected to be available in the U.S. in late 2024.
Also, Ligand Pharmaceuticals announced the appointment of Scott Plesha to the role of Chief Executive Officer. Prior to joining Pelthos, Plesha was President and Chief Commercial Officer at BioDelivery Sciences until it was acquired by Collegium Pharmaceutical in 2022.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.